Applying the ATN scheme in a memory clinic population
- 22 October 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 93 (17), e1635-e1646
- https://doi.org/10.1212/wnl.0000000000008361
Abstract
Objective To apply the ATN scheme to memory clinic patients, to assess whether it discriminates patient populations with specific features. Methods We included 305 memory clinic patients (33% subjective cognitive decline [SCD]: 60 ± 9 years, 61% M; 19% mild cognitive impairment [MCI]: 68 ± 9 years, 68% M; 48% dementia: 66 ± 10 years, 58% M) classified for positivity (±) of amyloid (A) ([18F]Florbetaben PET), tau (T) (CSF p-tau), and neurodegeneration (N) (medial temporal lobe atrophy). We assessed ATN profiles' demographic, clinical, and cognitive features at baseline, and cognitive decline over time. Results The proportion of A+T+N+ patients increased with syndrome severity (from 1% in SCD to 14% in MCI and 35% in dementia), while the opposite was true for A−T−N− (from 48% to 19% and 6%). Compared to A−T−N−, patients with the Alzheimer disease profiles (A+T+N− and A+T+N+) were older (both p < 0.05) and had a higher prevalence of APOE ε4 (both p < 0.05) and lower Mini-Mental State Examination (MMSE) (both p < 0.05), memory (both p < 0.05), and visuospatial abilities (both p < 0.05) at baseline. Non-Alzheimer profiles A−T−N+ and A-T+N+ showed more severe white matter hyperintensities (both p < 0.05) and worse language performance (both p < 0.05) than A−T−N−. A linear mixed model showed faster decline on MMSE over time in A+T+N− and A+T+N+ (p = 0.059 and p < 0.001 vs A−T−N−), attributable mainly to patients without dementia. Conclusions The ATN scheme identified different biomarker profiles with overlapping baseline features and patterns of cognitive decline. The large number of profiles, which may have different implications in patients with vs without dementia, poses a challenge to the application of the ATN scheme.This publication has 37 references indexed in Scilit:
- Preclinical AD predicts decline in memory and executive functions in subjective complaintsNeurology, 2013
- Classification of primary progressive aphasia and its variantsNeurology, 2011
- Amyloid-β(1–42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer DiseaseClinical Chemistry, 2010
- Diagnosis and management of dementia with Lewy bodiesNeurology, 2005
- Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementiaAnnals of Neurology, 2003
- Standardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasmaAmyloid, 2000
- Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)Neurology, 1996
- Vascular dementiaNeurology, 1993
- Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.Journal of Neurology, Neurosurgery & Psychiatry, 1992
- MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal agingAmerican Journal of Roentgenology, 1987